PolyPeptide Group AG
PPGN
Rank in Stocks
#6689
PolyPeptide Group AG operates globally as a contract development and... PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
Share Price
$49.22
Last synced: 2026-11-09
Market Cap
$1.63B
Change (1 day)
0.71%
Change (1 year)
63.82%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade PolyPeptide Group AG (PPGN)
Category
Healthcare
Operating Margin for PolyPeptide Group AG (PPGN)
Operating Margin as of November 2026 TTM: 6.98%
According to PolyPeptide Group AG's latest financial reports, its current operating margin (TTM) is 6.98%. At the end of 2025 the company had an operating margin of 1.89%.
Operating Margin history for PolyPeptide Group AG from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 6.98% | 269.31% |
| 2025 | 1.89% | -187.10% |
| 2024 | -2.17% | -80.93% |
| 2023 | -11.38% | -353.45% |
| 2022 | 4.49% | -80.26% |
| 2021 | 22.74% | 15.08% |
| 2020 | 19.76% | 19.32% |
| 2019 | 16.56% | 7.12% |
| 2018 | 15.46% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -97.22% |
DE
|
|
| 19.68% | -97.18% |
DE
|
|
| 13.26% | -98.10% |
JP
|
|
| 17.08% | -97.55% |
CH
|
|
| 14.92% | -97.86% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about PolyPeptide Group AG's operating margin
What is PolyPeptide Group AG's operating margin?
PolyPeptide Group AG's operating margin is 6.98%, as of Nov 2026.
What was PolyPeptide Group AG's operating margin in 2025?
In 2025, PolyPeptide Group AG's operating margin was 1.89%, compared with -2.17% in 2024.
How has PolyPeptide Group AG's operating margin changed since 2020?
From 2020 to 2025, PolyPeptide Group AG's operating margin was highest in 2021 (22.74%) and lowest in 2023 (-11.38%).
How does PolyPeptide Group AG's operating margin compare with similar companies?
PolyPeptide Group AG's operating margin (6.98%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.